News stories about Baxter International (NYSE:BAX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Baxter International earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.7950944187749 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Baxter International Inc. (BAX) – Investors Alert on Unusual Volume Move – Wall Street Morning (wallstreetmorning.com)
- Hot Stock’s Watch List – Baxter International Inc (NYSE: BAX) – Stocks Pen (stockspen.com)
- Durable Medical Equipment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025 (markets.businessinsider.com)
- Global Antiemetic Market Opportunities 2018: Astellas Pharma, Novartis AG, , Baxter International (marketwatch.com)
- Baxter International Inc. (BAX) Stock Try To Grab Potentials on Technical Facts – Investing News Update (investingbizz.com)
A number of brokerages have commented on BAX. Citigroup upped their price objective on shares of Baxter International from $66.00 to $70.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 6th. Barclays upped their price objective on shares of Baxter International from $73.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Deutsche Bank upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a research report on Tuesday, February 20th. JPMorgan Chase & Co. upgraded shares of Baxter International from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Finally, Royal Bank of Canada restated a “hold” rating and set a $66.00 price objective on shares of Baxter International in a research report on Wednesday, November 22nd. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $71.00.
Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.77 billion. Baxter International had a net margin of 6.79% and a return on equity of 15.11%. The business’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.57 EPS. analysts forecast that Baxter International will post 2.78 earnings per share for the current fiscal year.
Baxter International announced that its Board of Directors has approved a share buyback plan on Tuesday, February 20th that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 2nd. Investors of record on Friday, March 2nd will be paid a $0.16 dividend. The ex-dividend date of this dividend is Thursday, March 1st. This represents a $0.64 dividend on an annualized basis and a yield of 0.94%. Baxter International’s payout ratio is 49.61%.
In related news, SVP Giuseppe Accogli sold 28,641 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Carole J. Shapazian sold 4,990 shares of the stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $66.05, for a total transaction of $329,589.50. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://baseballnewssource.com/2018/03/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-baxter-international-bax-stock-price/1889440.html.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.